News

“The data continue to validate our hypothesis that izokibep offers differentiated efficacy with high potency and small size and reinforces izokibep’s potential to manage the hard-to-treat manifestations of PsA."

As cannabis use continues to rise worldwide, investigators question its role in treating fibromyalgia, a common pain syndrome that affects women twice as much as men.

Take 5 minutes to catch up on Rheumatology Network's highlights from the American College of Rheumatology Convergence 2022.

Personalizing non-pharmacological treatment for patients with fibromyalgia using a targeted symptom approach may improve outcomes.

Deucravacitinib showed sustained efficacy in the various outcomes in psoriatic arthritis and a unique and consistent safety profile.

Taking an integrative approach to management by using a combination of therapies and lifestyle changes to treat the whole person can have benefits for many conditions, such as cardiovascular disease and diabetes. How does this approach fit in with the management of rheumatoid arthritis? Test your knowledge with this quiz.

Deepak Bhatt, MD, MPH, discusses a posthoc analysis of the ORAL Surveillance trial examining drivers of increased cardiovascular risk observed in the phase 3b/4 trial in patients with rheumatoid arthritis.

The time of flare was significantly shorter in the placebo group compared to the baricitinib.

ASAS40 responses increased between week 16 and week 52 in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.

A trial comparing a 1-week methotrexate hold following seasonal influenza vaccination against the standard 2-week hold among patients with rheumatoid arthritis using methotrexate suggests there were no significant differences in positive vaccine response with either approach.

In this Q&A, Fabian Proft, MD, discussed the findings of his study that evaluated the DAPSA using a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis.

For safety, the proportions of patients with serious treatment-emergent adverse events in the second treatment period were similar between the treatment groups.

ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.

Data from a phase 2 trial presented at ACR Convergence 2022 provides clinicians with insight into the effects of deucravacitinib, a TYK2 inhibitor, in patient populations with systemic lupus erythematosus.

The results show 88.1% of patients with rheumatoid arthritis in the study developed humoral immunogenicity.

A post hoc subgroup analysis compared TNFi-IR patients receiving upadacitinib 15 mg once daily in 3 Phase 3 clinical trials: SELECT-BEOYND, SELECT-CHOICE, and SELECT-COMPARE.

A systematic review and meta-analysis presented at ACR Convergence 22 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus.

There was also a reduction in ultrasound features of gout at the knee identified, with improvement found in 63% of the tight control group and 14% of the conventional group.

There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.

Exposure to more than 100 mg was linked to significantly lower odds ratios for first-ever ACS event for women.

The results also show substantial medication substitution across prescription drug classes related to medical cannabis use.

Low levels of disease activity were achieved and increased throughout the study.

Data from the CONSUL trial provide insight into the effects of TNF inhibitor monotherapy compared against combination therapy with NSAIDs for blunting radiographic spinal progression in adults with radiographic axial spondyloarthritis.

The median time-to-remission was longer for women compared to men.

A significantly larger portion of patients in the telitacicept 160 mg achieved SR14 response compared to the placebo group.

An analysis of more than 17,000 Veterans suggests early initiation of TNF inhibitor therapy in patients with ankylosing spondylitis was associated with an increased risk of incident cardiovascular disease and major adverse cardiovascular events.

Individuals who were socially isolated at time of fracture had significantly worse function, ability to participate in social roles, and depression time of fracture.

Anti-osteoporotic treatment resulted in increased BMD to a greater extent in patients treated with less than 5 mg per day of prednisone.